4:37 PM
 | 
Jul 09, 2018
 |  BC Extra  |  Company News

Celgene's Golumbeski resurfaces, at Grail

Cancer detection company Grail Inc. (Menlo Park, Calif.) hired George Golumbeski as president and a director. Golumbeski joins Grail after his recent departure from Celgene Corp. (NASDAQ:CELG), where he served as EVP and executive adviser for innovation and was a key driver of the bellwether's prolific and creative partnering strategy.

Golumbeski is also a venture partner at Arch Venture Partners and executive adviser and board member at CRISPR company KSQ Therapeutics Inc. (Cambridge, Mass.), which launched in October.

Golumbeski departed Celgene in April along with President and COO Scott Smith. Last month, Celgene said CFO Peter Kellogg will retire in mid-2019. The management changes followed a tumultuous period beginning in October 2017 that has included the discontinuation of a Phase III trial of mongersen to treat Crohn's disease, the company's cut of its 2020 revenue guidance, and FDA issuing a refusal-to-file letter for an NDA for multiple sclerosis therapy ozanimod (see "Celgene Names Elkins CFO").

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD